Bioadaptives (BDPT) Shares Outstanding (Weighted Average) (2013 - 2026)

Bioadaptives has disclosed Shares Outstanding (Weighted Average) across 13 years of filings, most recently posting $12.0 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $12.0 million, up 124123.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.0 million (up 124123.91% YoY), and the FY2025 annual result was $12.0 million, up 46.17% from the prior year.
• Shares Outstanding (Weighted Average) came in at $12.0 million for Q1 2026 at Bioadaptives, roughly flat from $12.0 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $1.1 billion in Q2 2024 to a low of $9667.0 in Q1 2025.
• The 5-year median for Shares Outstanding (Weighted Average) is $60.7 million (2022), against an average of $281.2 million.
• Across the five-year window, Shares Outstanding (Weighted Average) slumped 100.0% in 2025 and surged 124123.91% in 2026, its largest moves.
• Bioadaptives' Shares Outstanding (Weighted Average) stood at $106.0 million in 2022, then plunged by 94.37% to $6.0 million in 2023, then surged by 37.57% to $8.2 million in 2024, then jumped by 46.17% to $12.0 million in 2025, then changed by 0.0% to $12.0 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $12.0 million (Q1 2026), $12.0 million (Q4 2025), and $10.9 million (Q3 2025), per Business Quant data.